TRANSVAC2: Improving and accelerating vaccine development in Europe

Catarina Luis and Monika Slezak

European Vaccine Initiative
EU-funded Infrastructure Project:
28 partners | 9 countries | 5 years
Provide to the vaccine R&D community:

- State-of-the-art scientific-technical vaccine development services
- Technical training
- Innovative vaccine research and development (R&D)
TRANSVAC aims to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of vaccine projects by implementing a permanent research infrastructure for early vaccine development.
Support innovation and development of human and veterinary, prophylactic and therapeutic vaccines

Accelerate vaccine development by developing & applying cutting-edge technologies

Offer training courses to provide fundamental and advanced knowledge in vaccinology

Develop a sustainable vaccine infrastructure accelerating vaccine R&D
TRANSVAC2: Activities

Trans-National Access Services

Joint Research Activities

Training

Networking
TRANSVAC2: Trans-National Access (TNA)

- Supports preclinical and clinical vaccine development
- Services and expertise provided by TRANSVAC2 partners
- Free-of-charge (with few exceptions)
- Services from few weeks to several months
- Services organised in Four Platforms:
  
  Technology | Immunocorrelates & Sytems Biology | Animal Models | Clinical Support
TRANSVAC2: How can apply?

• Public institutions, SMEs & industry

• Majority of Users **MUST** work in an institution established in an EU Member State or Associated State

• 20% of Users of a specific service can be of non-EU countries Associated to Horizon 2020

• Users **MUST** work in a different country than the TRANSVAC Service provider

• Users **MUST** openly disseminate the results generated with the support of TRANSVAC2.

   >>>> Applicants are encouraged to follow an integrated approach by applying for complementing services.
TRANSVAC2: Synergies

- Concerted Dissemination
- Joint calls (ERINHA)
- Joint workshops and trainings
- Sample sharing: check TRANSVAC website

RICH2 Webinar 06.03.2020
Instruct-ERIC is a distributed infrastructure of centres of excellence open to external users with access to state-of-the-art structural biology technologies, expertise and training.

- 14 Members
- 10 Centres
- 1 Observer
Instruct-ERIC provides access to high-end structural biology expertise and the technology for structural biology studies that have a key role in vaccinology:

- NMR spectroscopy
- Cryo-Electron microscopy
- X-Ray methods
- Nabody Production
- X-Chem fragment screening

Academic scientists from Instruct-ERIC member countries are eligible for funding for access to Instruct-ERIC services provided within TRANSVAC project.
TRANSVAC2: TRAINING

- **M1** Clinical vaccine development and biomanufacturing
- **M2** Human and Veterinary vaccine development
- **M3** Adjuvants and Vaccine Formulation
- **M4** Validity and comparison of animal models
- **M5** Statistics for Vaccine Evaluation
- **M6** Cytometry by time-of-flight (CyTOF)
- **M7** Flow cytometry
- **M8** In vivo Imaging
- **M9** Process Development and scale-up of viral vaccines
- **M10** Assay Development and Validation (SPR Technologies)
- **M11** Process development and scale-up of recombinant
- **M12** Requirements for GMP production
- **M13** Systems biology of vaccinology
- **M14** Regulatory aspects of vaccine development
TRANSVAC2: New vaccines faster

TRANSVAC2’s comprehensive approach catalyses optimization, sustainability and harmonization of the vaccine development workflow by driving Europe’s capacity in vaccinology (trainings) and providing high-value scientific and technical support services (TNA).

“TRANSVAC2, supporting the present and transforming the future of vaccine R&D landscape in Europe, while creating global (health) impact.”

RICH2 Webinar 06.03.2020
TRANSVAC2: Open Call

Training Modules

M13 Systems Biology of Vaccinology
June 25-26th, 2020 at University of Siena, IT

M14 Regulatory aspects of vaccine development
June 11-12th, 2020 at EATRIS, NL

Vaccine Development Services

TRANSVAC2 project offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use.

Apply Now!

RICH2 Webinar 06.03.2020
Find out more at transvac.org

Contact us transvacinfo@euvaccine.eu

Follow European Vaccine Initiative

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N° 730964.